Market Newsdesk

University
scientists
le
a
d
ing the

Evict Radon

study
are asking Canadians to trackhow much time they are spending at home before, during and eventually after the COVID-19 pandemic to help cancer researchers calculate howchanging residential exposure to radon — the second leading cause of lung cancer— will influence future rates of lung cancerin Canada.

CALGARY, Alberta, Nov. 17, 2020 (GLOBE NEWSWIRE) — Evict Radon, a Canadian non-profit organization and team of university scholars dedicated to solving Canada’s large and worsening radon-gas exposure problem, has launched a new survey to understand the global pandemic’s impact on residential radon exposure. All participants in their ongoing national radon testing study are eligible.

The study was developed by Evict Radon researchers Drs. Cheryl Peters and Aaron Goodarzi, professors at the University of Calgary’s Arnie Charbonneau Cancer Institute. This is Canada’s largest COVID-related analyses of shifting radon exposure. Their goal is to accurately predict the future burden of radon-induced lung cancer in Canada.

“The trend toward working from home has been slowly increasing over the past decade. But those numbers have shifted dramatically in 2020 due to the widespread changes caused by COVID-19,” said Goodarzi. “We are currently analyzing the impact of this sudden change.”

Radon is an invisible but radioactive gas that is produced in the ground. Normally, it dilutes to virtually nothing as it emerges in outside air, but our buildings can often concentrate radon to hazardous levels not normally seen in nature – thus, high radon exposure is a humanmade problem that is now the second leading cause of all lung cancers. 

Canada contains some of the highest radon-generating soils on our planet, with modern Canadian homes concentrating radon to increasingly high, cancer-causing levels. This trend continues to worsen, with Prairie provinces now being home to the second-highest radon-exposed population on this planet.

Preliminary work by researchers indicates a 35% jump in residential radon exposure from March 2020 onwards.

“Radon exposure at home tends to be higher compared to offices that are subject to occupational health and safety regulations,” said Peters. “To maintain safety for the current and future Canadian workforce, it is imperative for us to understand changes in radon exposure.”

Evict Radon encourages Canadians to help public cancer research efforts and test for radon through their national radon study. The team emphasizes how this is especially important during the 2020 pandemic. To determine the radon levels in your home, all one has to do is purchase a long-term (90 or more day) radon testing device. Radon tests require no electricity and are about the same size as a small hockey puck.

To learn more about radon and to join the national radon testing study, Canadians can visit www.evictradon.org. All participants enrolled in the national radon testing study are eligible to contribute to the ongoing pandemic-related radon study.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7eb3f757-f408-44e3-bf1d-4cf969dfb20a

Media Contact 
Weston Jacques 
Evict Radon 
403-836-2635
[email protected] 

VANCOUVER, British Columbia, Nov. 17, 2020 (GLOBE NEWSWIRE) — American Lithium Corp. (TSXV: LI) (OTCQB: LIACF) (Frankfurt: 5LA1) (“American Lithium” or the “Company”), a leading lithium exploration and development operator is pleased to report commencement of the phase III drill campaign to expand the current 5.37 million tonnes (Mt) Lithium Carbonate Equivalent (LCE) at the Company’s wholly owned TLC sedimentary lithium project in Nevada, USA. Further, the program will provide bulk material to continue independent testing and validation of existing work on economical production of lithium by both hydrometallurgical and thermal processing methods. To date, all holes drilled at TLC have intersected significant lithium.

A maiden pit constrained resource of 1.107 billion tonnes measured and indicated (“M+I”) plus 362 Mt Inferred was established through the phase I & II drilling program of 2019-2020. This program included 23 RC drill holes and 5 core holes to yield this 5.37 million tonnes LCE M+I and 1.76 million tonnes LCE Inferred at a 400 ppm cut-off grade. Already established as one of North America’s largest confirmed sedimentary resources, this TLC resource is open both to the north and west on existing claims. In July 2020, an additional 52 claims comprising 1,074 (+26%) acres contiguous to the existing TLC property were added to the project due to evidence that the lithium structures continue in these directions.

Boart Longyear Company of Glendale, Arizona is contracted to complete six 6” diameter sonic drill holes. Since the ore is close to the surface the holes will be no more than 400 feet in depth. Initially, the drilling will focus north and northwest in the existing resource to upgrade inferred resources into measured & indicated resources. This drilling will test the newly acquired claim block to potentially further expand the resource on the site.

A key benefit from the recovered core in this drilling program is the availability of significant bulk samples to validate and optimize the Company’s hydrometallurgical and thermal processing options. American Lithium continues to work on numerous attractive process variations to seek the optimum flow-sheet for planned economic studies early in 2021.

Mike Kobler, CEO of American Lithium, notes “This phase III drilling program offers a strong opportunity to extend the size of this lithium deposit. We are most enthusiastic that our particular mineralization may offer more than one advantageous cost effective production opportunity that can be a real game-changer to fulfill the critical and expanding need for domestic lithium production in North America.”

Please watch our corporate video at https://www.americanlithiumcorp.com/our-company/ and review our informative short project update videos and related background information at https://www.americanlithiumcorp.com/projects/tlc-nevada/.

About The TLC Project

The TLC sedimentary lithium discovery that transformed into an exploration and development project is located 12 kilometres northwest of Tonopah, Nevada, with easy access by paved highway. Work to date has identified a 5.3-million-tonne measured and indicated lithium carbonate equivalent resource, with an additional 1.7 million tonnes inferred, placing the Company’s resource amongst a handful of lithium deposits in North America capable of development. TLC is near the surface, relatively flat-lying and a free-digging lithium sedimentary deposit that the company expects to advance through an early-stage economic study in 2021. Neighboring the Crescent Dunes solar energy plant, the project is favourably located for future production given the immediate access to some of the cheapest electricity in Nevada and availability of local labor, raw materials and water.

About American Lithium Corp.

American Lithium is actively engaged in the acquisition, exploration and development of lithium deposits within mining-friendly jurisdictions throughout the Americas. The Company is currently exploring and developing the TLC project located in the highly prospective Esmeralda lithium district in Nevada. TLC is close to infrastructure, 3.5 hours south of the Tesla Gigafactory, and in the same basinal environment as Albemarle’s Silver Peak lithium mine, and several advancing deposits and resources, including Ioneer Ltd.’s (formerly Global Geoscience) Rhyolite Ridge and Cypress Development Corp.’s Clayton Valley project.

The technical information within this news release has been reviewed and approved by Bruce Kienlen, P.Geo., a consultant to the Company and a qualified person under National Instrument 43-101.

For more information, please contact the Company at [email protected] or visit our website at www.americanlithiumcorp.com.

On behalf of the Board,

American Lithium Corp.

Michael Kobler, Chief Executive Officer

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements


Statements in this release that are forward-looking information are subject to various risks and uncertainties concerning the specific factors disclosed here. Information provided in this release is necessarily summarized and may not contain all available material information. All such forward-looking information and statements are based on certain assumptions and analyses made by American Lithium management in light of their experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. These statements, however, are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information or statements. Important factors that could cause actual results to differ from these forward-looking statements include those described under the heading “Risks Factors” in American Lithium’s most recently filed MD&A. The Company does not intend, and expressly disclaims any obligation to, update or revise the forward-looking information contained in this news release, except as required by law. Readers are cautioned not to place undue reliance on forward-looking information or statements.

CARY, N.C., Nov. 17, 2020 (GLOBE NEWSWIRE) — Chiesi USA (key-ay-zee), a specialty pharmaceutical company based in Cary, N.C., is proud to once again support March of Dimes in its mission to improve the health and lives of moms and babies during November’s Prematurity Awareness Month observance. In the U.S., one in 10 babies is born prematurely, and Chiesi is committed to helping close that gap through education and support of families, healthcare professionals and communities.

This month, Chiesi will serve as a Gold Sponsor of the 2020 March of Dimes Signature Chefs Auction. Each year, this signature event celebrates culinary excellence with top chefs from the Eastern North Carolina area featuring tastings of their creations for event supporters. This year, the event will be held virtually, and supporters will have the opportunity to experience meals at home by visiting select restaurants to pick up a dine-at-home meal. Money raised during the Signature Chefs event supports work to nourish all aspects of motherhood – from prenatal to postpartum – by ensuring all pregnant moms have access to care, addressing inequity in maternal health and strengthening moms, babies and families across America.

As part of Chiesi’s sponsorship, and in partnership with the Butcher’s Market in Cary, meals will be provided to families in the NICU at WakeMed Cary Hospital.

“Chiesi has a longstanding commitment of providing therapies for preterm babies in the NICU and working with March of Dimes to help reduce the number of babies born prematurely,” said Ken McBean, President and Chief Executive Officer. “For families spending days and weeks in the NICU it can be a very scary and isolating time, and the COVID-19 pandemic only increases that. We are proud to partner with the Butcher’s Market to support these local families as they care for their newborns.”

“Chiesi has been stepping up for moms and babies in Eastern North Carolina for more than six years,” added Jeff Sebastianelli, Board Chair of March of Dimes Eastern North Carolina. “With their support and funding, March of Dimes has been able to implement life-saving medical research that leads to healthy moms and strong babies. Chiesi’s commitment has ensured a brighter future for these families in our community.”

March of Dimes is one of several nonprofits supported by Chiesi’s employee-led corporate social responsibility program, Chiesi in the Community (CITC). Chiesi USA’s commitment to corporate philanthropy is solidified in Chiesi Group’s achievement of Certified B Corporation® status in 2019. The B Corporation Certification is awarded by the nonprofit B Lab, which assessed the social and environmental performance of all 28 Chiesi affiliates on the basis of the B Impact Assessment, the most widely used assessment for measuring the impact of a company on its workers, community, environment and customers. Chiesi is the largest multinational pharmaceutical group to become a Certified B Corporation®.

About Chiesi USA

Chiesi USA, Inc., headquartered in Cary, North Carolina, is a specialty pharmaceutical company focused on commercialization of products for the hospital and target office-based specialties. The Company is a wholly-owned subsidiary of family-owned Chiesi Farmaceutici S.p.A, a global R&D-focused pharmaceutical company based in Parma, Italy. In the United States, the Company delivers therapies and enhances care for patients in the areas of acute cardiology, neonatology and cystic fibrosis. Recognized as a Certified B Corporation®, Chiesi is dedicated to improving the health and well-being of its communities through its employee-led corporate social responsibility program, Chiesi in the Community. Innovation, collaboration and impact are the cornerstones of the Chiesi culture. For more information, visit www.chiesiusa.com.

Contacts

Media: FleishmanHillard, Elizabeth Comtois, (919) 334-3786, [email protected]
Chiesi USA: Michael Wasyluk, (919) 678-6611, [email protected]

Chiesi Farmaceutici, S.p.A.©2015 Chiesi USA, Inc. All rights reserved. PP-G-0506 V1.0

PDF Available: http://ml.globenewswire.com/Resource/Download/c9a4a584-e439-405a-ac72-53b3993127e7

LONDON and NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) — Smart Communications™, the only provider of a customer conversations management platform, today announced survey results uncovering consumer and business leader opinions about the current state of customer conversations in the U.S. and U.K. The research revealed consumers’ increasing preference for digital interactions with industries such as financial services, insurance and healthcare, the impact COVID-19 has had on consumer demands, and disparities between what companies think they are delivering as compared to consumers’ expectations.

“As the business world raced to respond to a new set of needs tied to COVID-19, delivering end-to-end, digital-first customer experiences became increasingly important,” said James Brown, CEO of Smart Communications. “It’s no secret that companies that prioritized digital transformation efforts aimed at improving customer conversations have a more meaningful edge today than ever before – and yet, our study uncovered several key areas that businesses must continue to focus upon in order to meet evolving consumer needs during these unprecedented circumstances.”

Key findings from the new research report, Customer Conversations in 2020: New Challenges, Changing Expectations and Accelerated Digital Transformation, include:

Businesses Attempting to Meet Digital Demands

The study found that 86 percent of consumers prefer digital interactions to other forms of communications. And for some, the events of 2020 had a direct impact on channel preferences. Nearly 40 percent of consumers in the U.S. indicated they changed their preference from direct mail to digital communications due to factors related to the COVID-19 pandemic – and consumers aren’t the only group making a shift to digital. Seventy-two percent of business leaders said that they plan to shift away from print-based communications and more fully embrace digital, with 76 percent now budgeting to make customer communications more mobile-friendly.

While the need for digital transformation didn’t just arise this year, the global health crisis certainly deepened the sense of urgency. Sixty-five percent of business leaders indicated that COVID-19 led them to identify digital-first approaches they could implement quickly.

Transformed
Forms Experience Key for Consumers

Data collection and forms processes were among the tasks most significantly impacted by stay-at-home orders, closed businesses and remote workforces. When in-person meetings became impossible, relying on consumers to provide accurate information remotely as part of common business processes such as new account opening, onboarding, and filing claims became more important than ever – and consumers’ desire for these interactions to be frictionless and digital-focused are clear.

The study found that nearly 60 percent of consumers are likely to abandon a form if the process is too difficult. In turn, 72 percent of businesses said that they are looking to streamline data collection processes to improve the customer experience and to reduce form abandonment rates.

Businesses and Consumers Disagree
About
Communications Performance

Despite recent investments and improvements, the study also revealed a significant disparity between businesses’ and consumers’ opinions about the quality of communications currently being distributed. Only 51 percent of customers say the communications they are receiving are above average – either “excellent” or “very good” – while 63 percent of business leaders say they would rate their communications with customers similarly. This disparity should be of utmost concern with more than half of survey respondents indicating they are likely to switch vendors if their communications goals are not met.

“The results of our study confirmed that consumers desire more meaningful conversations with the companies they conduct business with, and that they have strong opinions about how to make those interactions exceptional,” Brown added. “Creating customer experiences that are personalized, timely and delivered via channels of choice, which are increasingly digital, is no longer a nice-to-have, but is critical to success.”

For more survey results and to obtain actionable insights for having smarter customer conversations, download the complete study here.

Survey Methodology:

Smart Communications commissioned Harris Interactive to survey consumers in the UK and U.S. about communications in financial services, insurance and healthcare. In the fall of 2020, Smart Communications targeted fields of nationally representative consumers in both the U.S. (605 respondents) and the UK (555 respondents) who use companies in at least one of the three sectors. B2B research (204 interviews were completed in the UK and 299 in the U.S.) was conducted within financial, insurance or private healthcare companies with employees at management level or above and who are familiar with the communications their company sends out.

About Smart Communications

Smart Communications™ is the only provider of a customer conversations management platform. More than 500 global brands rely on Smart Communications to deliver smarter conversations across the entire lifecycle—empowering them to succeed in today’s digital-focused, customer-driven world while also simplifying processes and operating more efficiently. This is what it means to scale the conversation. Smart Communications is headquartered in the UK and serves its customers from offices located across North America, Europe, and Asia Pacific. The Smart Communications platform includes the enterprise-scale customer communications management power of SmartCOMM™, forms transformation capabilities made possible by SmartIQ™ and the trade documentation expertise of SmartDX™. To learn more, visit smartcommunications.com.

Media Contact

Stacy Kirk
[email protected]
+1 770-891-9285

NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) — Tremor Video, the leading programmatic video platform, today announced that the number of clients using its self-service DSP has more than doubled and self-service ad spend has increased by 650% since Q3 2019. Following Tremor Video’s investment in platform enhancements, increasing advertiser demand has reinforced the company’s DSP as an efficient, flexible and streamlined platform to execute ads across all screens and devices. New enhancements include quick and bulk editing tools and programmatic guarantees, which enable direct 1:1 deals with publishers.

Overall, digital ad spend has slowed down (forecasted to increase 1.7% in 2020), which makes this growth exceptionally significant with revenue generated by Tremor Video’s self-service DSP forecasted to increase by 557% in Q3 2020. In addition to increased advertiser engagement with Tremor Video’s connected TV (CTV) and automatic content recognition (ACR) offerings, the integration of sister brand Unruly is one of the main drivers of growth — combining the supply footprints, which includes over 3,000 direct premium publisher partnerships.

As advertisers continue to invest in video across all screens, Tremor Video’s self-service DSP delivers end-to-end benefits by providing tools for easy activation and quick changes, bidding logic that delivers key performance outcomes, access to differentiated audience data and exclusive high-quality supply. Additionally, Tremor Video has seen a rise in retailers and direct-to-consumer (DTC) brands leveraging the platform to seize on the e-commerce momentum as consumers increasingly shop online as a pandemic safety precaution.

“Tremor Video’s self-service DSP allows us to be an even stronger partner for our brand clients by ensuring their ad campaigns reach the most highly-targeted audience possible,” said Tim Lathrop, Digital Director at Mediassociates. “It affords us a greater sense of ownership over these campaigns, while helping us execute more efficiently and providing key insights we can use to optimize performance, all in an easy-to-use platform.”

Key benefits of Tremor Video’s self-service DSP include:

• All-screen video platform to enable the execution of impactful ads across multiple screens with just a single placement
• Direct and exclusive access to premium video and connected TV (CTV) supply
• Easy-to-use UI to streamline campaign setup, activation and optimization
• Machine-learning predictions to deliver the best KPI outcomes for each campaign, including video completion rate, click-through rate and engagement rate
• Exclusive automatic content recognition (ACR) and emotion-based EQ consumer data to reach unique audiences across all screens
• Enhanced brand storytelling with custom creative solutions to drive engagement

“The growth of our self-service DSP is the direct result of our ongoing strategy to expand our video advertising capabilities in the areas that will most benefit our clients including CTV and private marketplaces (PMPs),” said Karim Rayes, Chief Product Officer, Tremor Video. “Advertisers are increasingly seeking control and transparency — a trend that the anxiety brought on by the pandemic is only spurring on more. Tremor Video continues to invest in our self-service DSP to allow advertisers to keep responsibility for their businesses in their hands.”

About Tremor Video

Tremor Video helps advertisers deliver impactful brand stories across all screens through the power of innovative video technology combined with advanced audience data and captivating creative. Tremor Video is one of the largest and most innovative video advertising companies in North America, with offerings in CTV, instream and in-app. Tremor Video is a Tremor International company.

Media Contact

Brook Terran
805-570-3309

BOSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) — LogMeInInc., the work-from-anywhere company, is announcing a new global sustainability program designed to mitigate the company’s operational impact on the environment.   LogMeIn’s suite of products helps businesses stay connected in a rapidly changing world, and the sudden shift to remote work, necessitated by the pandemic, caused unprecedented spikes in LogMeIn’s product usage around the globe. The environmental benefits of this shift were also significant. LogMeIn has examined this new work paradigm and expanded its sustainability programs in order to account for all employee work options: remote, office-based, or a combination of the two.

When the pandemic hit, many organizations switched to remote work. Despite the uncertain times, there were key positive takeaways: emissions reductions and increased employee engagement. Fewer cars on the road and airplanes in the skies led to cleaner air and, often, happier and more productive employees. The perception of what is possible when it comes to working from home has changed, increasing the number of virtual meetings, redefining face-to-face interactions, and reducing travel.

“We initially started looking at our sustainability goals before anyone knew the massive impact the pandemic had on how, and where, we all work. What we quickly realized was that the acceleration in the remote work trend could have a very real and lasting positive impact on our environment and we are proud to be able to play a small role in enabling that shift,” said Bill Wagner, President and CEO, LogMeIn. “In looking at our own sustainability practices as an organization, we wanted to not only rethink where and how we use office space, and to make those spaces as environmentally friendly as possible, but also apply those same goals and best practices to our employees’ homes, where the majority of our workforce will be based moving forward. Our announcement today is the first step in bringing that vision of creating more sustainable places and practices for our people to fruition.”

As LogMeIn moves to a remote–centricwork model, the company is doubling down on its commitment to sustainability by announcing several new programs focused on both corporate and home office spaces and employee engagement:

• LogMeIn will explore opportunities to participate in new renewable energy efforts while beginning to procure renewable energy certificates (RECs)
  with a goal of
  moving towards Net Zero by 2030. Starting in 2021, we will match 100% of our entire global electricity usage–including the estimated electricity usage of all employees working from home–with third party certified RECs. As the company grows, we will continue to explore new renewable energy opportunities while striving to mitigate our emissions with a goal of moving towards Net Zero by 2030.

• As the work-from-anywhere company, LogMeIn will
  lead by example and
  continue to reduce and offset all business travel emissions. Like many businesses, our work travel has been permanently altered by the pandemic. At LogMeIn, our technology will continue to replace the majority of face-to-face interactions with virtual meetings, though the company recognizes the necessity of business travel and in-person collaboration in certain situations. We take business travel emissions seriously, and will continue to procure certified carbon offsets to mitigate all emissions that we are unable to eliminate.

• LogMeIn will c
  ontinue to work with secure, efficient,
  and
  remote data centers that operate sustainab
  ly
  . We will prioritize running operations through data centers with high energy efficiency standards, high ratings from Greenpeace, with a goal of using 100% clean and renewable energy for our global products.

• LogMeIn will c
  omplete
  an
  environmental, social
  ,
  and governance (ESG)
  materiality assessment by the first half of 2021. This assessment will help LogMeIn identify which ESG issues we should prioritize. As part of this process, we are working with a third party, Sustainability Roundtable, Inc., to conduct confidential interviews with senior executives from across business lines and control functions.

• LogMeIn’s
  recent announcement
  of a
  shift to a
  
  remote-centric workforce
  means our employees will spend less time commuting, use less fuel, and create fewer emissions. With the new work policy, most employees will only commute to an office a few times per month for collaborative meetings. In such instances, LogMeIn has committed to purchasing certified carbon offsets to cover the resulting emissions.

• LogMeIn has launched a campaign in which all LogMeIn employees are invited to complete a personal pledge to reduce their own emissions while at home. For every pledge card completed, LogMeIn will plant five trees through the Arbor Day Foundation’s Time for Trees initiative.

• By Earth Day 2021, LogMeIn will further engage employees by expanding sustainability training and by organizing global green teams. We will launch employee sustainability training, engagement programs, and global green teams aimed at arming our more than 3,500 employees with the latest sustainability information, as well as best practices for reducing their environmental footprint not just in the office, but at home as well. This training is more important than ever, as remote-centric work has been permanently instituted at the company, and employee engagement is critical to the success of the Company’s sustainability goals.

Jim Boyle, CEO & Founder of Sustainability Roundtable, Inc. – a shared-cost industry leadership service that assists LogMeIn – remarked: “LogMeIn is well positioned to help play a catalytic role in our urgently needed transition to a Net Zero Emissions economy. LogMeIn has developed an impressive and practical program to reduce its greenhouse gas pollution and help its employees and customers do the same around the world. LogMeIn is demonstrating that businesses can, in accord with the United Nations Sustainable Development Goals, ‘Build Back Better’ from the Covid-19 pandemic.”

LogMeIn will also continue to invest corporate social responsibility (CSR) funds in non-profit organizations that are working towards a greener future including, but not limited to, The Ocean Conservancy, Environmental Defense Fund, and small grassroots organizations in our local communities.

For more information on LogMeIn’s sustainability and CSR program, please visit: www.logmeininc.com/corporate-social-responsibility

About LogMeIn, Inc.

LogMeIn, Inc.’s category-defining products unlock the potential of the modern workforce by making it possible for millions of people and businesses around the globe to do their best work simply and securely—on any device, from any location and at any time. A pioneer in remote work technology and a driving force behind today’s work-from-anywhere movement, LogMeIn has become one of the world’s largest SaaS companies with tens of millions of active users, more than 3,500 global employees, over $1.3 billion in annual revenue and approximately 2 million customers worldwide who use its software as an essential part of their daily lives. The company is headquartered in Boston, Massachusetts with additional locations in North America, South America, Europe, Asia and Australia.

Media Contact:

Jen Mathews
[email protected]  

Rapid Enrollment Expected


,


As Many


People


Have Already Volunteered

VANCOUVER, Washington, Nov. 17, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it has filed a protocol with the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical trial for leronlimab as a treatment for COVID-19 patients suffering from long-hauler symptoms.

According to a recent article from The Journal of the American Medical Association and a study done by British scientists, researchers estimate about 10% of COVID-19 patients become long-haulers. Published studies and surveys conducted by patient groups indicate 50% to 80% of patients continue to have troublesome symptoms three months after the onset of COVID-19 — even after tests no longer detect virus in their body. The list of long-hauler symptoms is extensive and inconsistent. For some people, the lingering symptoms are nothing like the original symptoms when they were first infected with COVID-19. The most common long-hauler symptoms include:

• Coughing
• Ongoing, sometimes debilitating, fatigue
• Body aches
• Joint pain
• Heart issues
• Shortness of breath
• Loss of taste and smell
• Difficulty sleeping
• Headaches
• Brain fog

CytoDyn’s protocol for its Phase 2 COVID-19 long-haulers trial is entitled: ”A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients Experiencing Prolonged Coronavirus Disease 2019 (COVID-19) Symptoms [Long-Haulers].” The planned number of patients is 102 to be enrolled in up to 10 sites. The study will have an interim analysis after half of the patients are enrolled and will allow CytoDyn to report the results.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We are very pleased to be able to finalize this protocol and submit today. Many thanks to Drs. Chris Recknor, Mahboob Rahman and Kush Dhody for spending countless hours over the last six weeks finalizing this very challenging trial protocol. Dr. Recknor’s past enrollment of patients in our CD10 trial was critical to his understanding of what leronlimab can do and his experience with those patients greatly assisted us to design and finalize this protocol. If successful, this Phase 2 trial could potentially allow leronlimab to be the first treatment for patients experiencing these debilitating symptoms and perhaps their only hope for full recovery. We have become very knowledgeable of leronlimab’s potential for COVID-19 patients due to our completed Phase 2 trial for mild-to-moderate symptoms, for which a complete report has been submitted to a very reputable journal for publication.”

About Coronavirus Disease 2019

CytoDyn completed its Phase 2 clinical trial (CD10) for COVID-19, a double-blinded, randomized clinical trial for mild-to-moderate patients in the U.S. which produced statistically significant results for NEWS2. Enrollment continues in its Phase 2b/3 randomized clinical trial for the severe-to-critically ill COVID-19 population in several hospitals and clinics throughout the U.S., which are identified on the Company’s website under the “Clinical Trial Enrollment” section of the homepage; an interim analysis on the first 195 patients was conducted mid-October and is expected to occur again after enrollment reaches 293 patients.

About Leronlimab (PRO 140)

The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for critical illnesses. The first indication is a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people and met its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients). 

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use. 

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.  

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to leronlimab for the prevention of GvHD. 

About CytoDyn

CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH.

CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. The FDA met telephonically with Company key personnel and its clinical research organization and provided written responses to the Company’s questions concerning its recent Biologics License Application (“BLA”) for this HIV combination therapy in order to expedite the resubmission of its BLA filing for this indication.

CytoDyn has completed a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV. No drug-related serious site injection reactions reported in about 800 patients treated with leronlimab and no drug-related SAEs reported in patients treated with 700 mg dose of leronlimab. Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than six years.

CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at www.cytodyn.com. 

Forward-Looking Statements 

This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict.  Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to have positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Company’s cash position, (ii) the Company’s ability to raise additional capital to fund its operations, (iii) the Company’s ability to meet its debt obligations, if any, (iv) the Company’s ability to enter into partnership or licensing arrangements with third parties, (v) the Company’s ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Company’s ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Company’s clinical trials, (viii) the results of the Company’s clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company’s products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Company’s control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CONTACTS

Investors:

Michael Mulholland
Office: 360.980.8524, ext. 102
[email protected]

WASHINGTON, Nov. 17, 2020 (GLOBE NEWSWIRE) — Eaglebrook Advisors, Inc (“Eaglebrook”) announced today that Mariner Wealth Advisors will make the Eaglebrook Bitcoin SMA available for clients who want access to bitcoin as part of their investment plan. Mariner Wealth Advisors is a national wealth advisory firm, with more than $35 billion assets under advisement¹, that has been ranked in the top five RIAs by Barron’s for the last five years².

Based in Washington, D.C., Eaglebrook is a crypto-focused investment firm that serves registered investment advisors (RIAs) and financial advisors. Eaglebrook is proud to announce the launch of the Eaglebrook Bitcoin SMA which will allow financial advisors to allocate to bitcoin in a simple and secure way³. The advantages of the Eaglebrook Bitcoin SMA include tax optimization, direct ownership, and portfolio integration. Eaglebrook streamlines client onboarding, movement of funds, trade execution, reporting data aggregation, rebalancing, and tax documentation. This investment solution allows financial advisors to include bitcoin in their clients’ asset allocation strategy and overall financial plan.

“We are excited to offer this new solution to clients of Mariner Wealth Advisors where bitcoin fits into their overall wealth plan,” said Marty Bicknell, CEO and president of Mariner Wealth Advisors. “Our desire to find new solutions is always driven by client need and we are looking forward to working with Eaglebrook on this new endeavor.”

Demand for bitcoin from financial advisors and their clients has accelerated due to current trends, including the growth in investment demand from millennials and institutional investors, bitcoin’s potential as an inflation hedge in response to monetary stimulus and the asymmetric upside of the investment.

“We are thrilled to be working with Mariner Wealth Advisors,” said Christopher King, CEO of Eaglebrook Advisors. “Our investment solution, designed to meet the unique needs of firms such as Mariner Wealth Advisors, makes it easy for their advisors to allocate to bitcoin. We expect cryptocurrency adoption to continue and the market to mature, driving even greater demand.”

Eaglebrook has selected Gemini Trust Company, LLC (“Gemini”) as the qualified custodian for the Eaglebrook Bitcoin SMA. The client’s bitcoin is owned directly and is stored in an offline, institutional-grade custody account at Gemini.

“We are very pleased to have been selected as Eaglebrook’s custodian to help them provide RIAs a secure way to store their digital assets. These types of solutions are critical to provide more financial advisors exposure to digital assets,” said Noah Perlman, Chief Operating Officer at Gemini.

Media Contact

Christopher King
[email protected]
+1 (202) 744-0774

About
Eaglebrook
Advisors

Eaglebrook is a crypto-focused investment firm that serves registered investment advisors (RIAs) and financial advisors. The crypto-focused investment firm has launched the Eaglebrook Bitcoin SMA which allows financial advisors to allocate to bitcoin in a simple and secure way³. Eaglebrook is backed by top wealth management executives including Marty Bicknell, Mark Casady, and Joseph Mrak.

About Mariner Wealth Advisors

At Mariner Wealth Advisors, we focus on providing 360° advice designed to last. We focus on one thing—partnering with clients to create a financial strategy for today and beyond that’s flexible enough to change along with them. The ultimate goal? Helping clients identify what is important so they achieve their goals—we’re committed to being here for everything life brings their way. We’ve built our firm around what our clients need. We began by offering wealth planning resources and then added services from tax planning to insurance – under one roof. We believe this integrated approach to wealth management helps simplify our clients’ lives. Founded in 2006 with $300 million in assets under advisement, Mariner Wealth Advisors has grown to more than $35 billion in assets under advisement (as of 9/30/20).

¹Mariner Wealth Advisors’ AUA as of 9/30/20.

²
Barron’s awarded the 2020 #5, 2019 #4 and 2018 #3 Top RIA Firms rankings to Mariner Wealth Advisors based on data compiled for Mariner Wealth Advisors and the 2017 #2 and 2016 #1 rankings to Mariner Holdings based upon data compiled for Mariner Holdings’ registered investment adviser subsidiaries. The number of firms included in the rankings were: 20 (2016), 30 (2017), 40 (2018), 50 (2019) and 100 (2020). Barron’s publishes rankings based upon a number of criteria and the firms’ filings with the SEC were used to cross-check the data provided. The listing includes numbers of clients, employees, advisors, offices and state locations. The award is not indicative of future performance and there is no guarantee of future investment success. For additional information visit www.barrons.com. 

³The client’s bitcoin held in the Eaglebrook Bitcoin SMA is secured in an offline, institutional-grade custody account at Gemini. Gemini is a fiduciary and qualified custodian under New York Banking Law and is licensed by the State of New York to custody digital assets.

ST. GEORGE, Utah, Nov. 17, 2020 (GLOBE NEWSWIRE) — MedLite ID is very pleased to announce healthcare sales veteran, Bruce Thompson, joins the firm as Vice President of Sales. Bruce’s responsibilities will encompass sales team leadership, accelerating MedLite ID’s revenue through expanding their presence in new geographies, management of distribution partnerships, and contributing to the company’s marketing and business strategies.

Bruce brings over 30 years of sales and leadership experience to MedLite ID, with 15 of those years focusing on the healthcare industry.  Prior to joining MedLite ID, Bruce gained expertise growing and leading high-performance sales teams in North American and globally for companies such as Unitron Hearing and Pella Windows. Bruce’s strong experience working with direct and distribution sales as well as healthcare group purchasing organizations will be a huge benefit for MedLite ID.

“Bruce is an outstanding addition to our MedLite ID team, as he brings a deep blend of dynamics channel experience and knowledge of what it takes to deliver client success,” said Rodney Schutt, CEO of MedLite ID. “As MedLite ID continues its rapid growth and focuses across the United States and globally, Bruce’s sales leadership and his strong background in building top performing sales partnerships will accelerate MedLite ID’s growth. We are thrilled to have him onboard!” stated Schutt.

“I am honored to join the MedLite ID team and help to build on the solid foundation Rodney and team have developed.  MedLite ID is perfectly positioned to help its clients protect both patients and clinicians from harm and save healthcare facilities time and money,” stated Bruce Thompson, Vice President of Sales, MedLite ID. He continued, “As an organ transplant recipient, I understand the uniqueness and the benefits of the product first-hand.”

About MedLite ID
MedLite ID is a medical device manufacturer partnered with University of Notre Dame and Dixie State University to develop a unique solution designed to light the primary medication infusion line (sometimes referred to as the safe push line) in a visually distinct and easily identifiable way to help prevent “infusion confusion”, reduce the risk of medical errors, improve patient safety and dramatically enhance clinician productivity. For more information on MedLite ID, please visit www.medliteid.com

Media Contact:

Terri Greulich
Director of Marketing
[email protected]
833.288.5489

 

BOSTON and LONDON, Nov. 17, 2020 (GLOBE NEWSWIRE) — Pioneer Consulting, the full-service submarine fiber optic telecommunications consulting and project management company, announces successful completion of owner’s representation on the CrossChannel Fibre project marine route survey on behalf of project developer Crosslake Fibre. The survey, conducted by EGS, is a major construction milestone for the first fiber optic submarine cable to be built across the English Channel in nearly 20 years.

Pioneer Consulting is providing system integration services for the disaggregated CrossChannel Fibre project, supporting the on-time overall delivery of the subsea portion of the project. This work follows Pioneer’s authorship of the Request for Proposals (RFP) and oversight of the bidding process. Pioneer Consulting used its deep technical and commercial experience to develop a detailed technical specification of all aspects of the survey, then assessed a multitude of qualified respondents before choosing EGS as the preferred supplier.

The marine route survey included geotechnical, geophysical, and unexploded ordnance surveys that sought a route optimized for cable protection, avoidance of obstructions, and in respect of the needs of the national and local governments of both the United Kingdom and France. Designed to optimize the route for resilience, the system will provide users with enhanced bandwidth capacity at lower operating costs.

The survey required more than a dozen pieces of specialized equipment to accurately portray the ocean floor. Terabytes of data are now being reviewed to inform the final route for cable installation.

“This is a pivotal moment for such a groundbreaking project,” said Iain Ritson, Pioneer Consulting’s Director of Client Solutions and Project Director for CrossChannel. “These unique times have made it clearer than ever how essential it is to have fast, secure, reliable telecommunications bandwidth for our society to thrive and stay connected. We are honored to be working again with Crosslake Fibre to forge a new path across the English Channel that will provide significantly enhanced capacity during this critical time.”

“There is a tremendous need across the globe for new, creative solutions to telecommunications challenges. The CrossChannel Fibre project will provide critical infrastructure relied upon by millions of people and businesses at a time when it is most needed. Our size and experience allow us to utilize industry-leading suppliers at every level of the project. Our contractors often operate as an extension of our own team, and Pioneer Consulting’s project management services have been instrumental as we execute this mission-critical project,” stated Mike Cunningham, CEO of Crosslake Fibre.

The submarine fiber optic cable will connect the London suburb of Slough, UK and Paris, France. It is designed to support the increase in bandwidth requirements from telecommunications and other enterprises, content providers, financial, gaming, and media companies that require high-capacity, low-latency connectivity. The high-fiber-count, non-repeatered system will contain 96 fiber pairs, each providing over 20 terabits per second of throughput capacity.

About Pioneer Consulting


Pioneer Consulting
offers a comprehensive set of services for the submarine fiber optic telecommunications system industry. The company provides clients with valuable technical and commercial insight into the challenging issues facing this unique industry. Recognizing the diverse nature of the submarine telecommunications marketplace, Pioneer Consulting has built a team of industry-leading experts who are able to work across traditional boundaries and provide businesses with the strategic intelligence and operational skills needed to make long-term business decisions and deliver results.

About Crosslake Fibre


Crosslake Fibre
was established to develop, own, and operate fiber-optic projects throughout North America and Western Europe. Using new methods of construction to develop next-generation networks, Crosslake Fibre has built new Internet infrastructure that provides material advantages to customers.

Media Contact

Eugene Hunt
Trevi Communications for Pioneer Consulting
[email protected] 
+1-978-750-0333